NEUVIOR Pharmaceuticals new sustainable drug trials

NEUVIOR Pharmaceuticals started feasibility testing at the Biorenewables Development Centre (BDC) in York on April 17, supported by a recent funding award from Innovate UK, which will last until April 21.

Varun Cruz, founder of NEUVIOR, said: “ZYLON is about turning early-stage ideas into real, testable data.

“This feasibility work allows us to validate core assumptions in a live lab environment and define a credible path toward more circular pharmaceutical manufacturing.”

The ZYLO programme is focused on recovering material from pharmaceutical manufacturing processes and developing smarter, bio-based packaging materials that could replace harder-to-recycle formats.

It forms part of a wider project, VIONIX ZERO, which aims to reduce waste and lower carbon emissions in pharmaceutical production.

The current trials are exploring bio-derived inputs and de-risking potential approaches that could underpin more circular pharmaceutical manufacturing systems.

Mark Gronnow, Process Development Team Lead at the Biorenewables Development Centre, said: “The BDC is happy to support NEUVIOR on their development journey of an exciting biobased product range.

“Being able to rapidly and flexibly support innovators with facilities and resources is one of our specialisms.”

The work at the BDC will provide the early-stage data needed to inform future development and scale-up plans.